Last reviewed · How we verify
CDP7657
At a glance
| Generic name | CDP7657 |
|---|---|
| Sponsor | UCB Pharma |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- COVID-19
- Nasopharyngitis
- Diarrhoea
- Urinary tract infection
- Upper respiratory tract infection
- Headache
- Nausea
- Herpes zoster
- Oral herpes
- Bronchitis
Key clinical trials
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHASE3)
- Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus (PHASE1)
- Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDP7657 CI brief — competitive landscape report
- CDP7657 updates RSS · CI watch RSS
- UCB Pharma portfolio CI